Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 6/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246019 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL1246010 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| Formic Acid SCHEMBL28823054 | 0.94 | ADRB2 (0.63) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL1244738 | 0.85 | KMT2A (0.57) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL1244737 | 0.85 | KMT2A (0.57) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL4983780 | 0.85 | ADRB2 (0.55) | ADRB2ADRB1ADRB3ALDH1A1MAPT | |
| SCHEMBL19206103 | 0.84 | ADRB2 (0.57) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL8405253 | 0.84 | ADRB2 (0.64) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL2336328 | 0.83 | ADRB2 (0.71) | ADRB2ADRB1ADRB3KMT2AMEN1 | |
| SCHEMBL11774862 | 0.82 | ADRB2 (0.55) | ADRB2ADRB1ADRB3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3948972-A | WITH GLYCEROL, ACID CATALYST | BAKER JAMES ALBERT | 1976-04-06 | — | — | US | claimed |
| WO-2011012400-A2 | NITRIC OXIDE RELEASING NAPROXEN | NICOX S.A. (FR) | 2011-02-03 | — | — | WO | disclosed |
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-3948972-A | WITH GLYCEROL, ACID CATALYST | BAKER JAMES ALBERT | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | PTGS2, PTGS1, PTGES2 | ADRB2 2038/4885ADRB1 2976/4885ADRB3 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.